Disappearance of the hyperdense MCA sign after thrombolysis: is it a predictor of better prognosis in patients with acute ischaemic stroke?
Shuaib
Ashfaq
A
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007262:Infusions, Intravenous; D009460:Neurologic Examination / Q000187:drug effects; D011379:Prognosis; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator